Literature DB >> 28774478

Putting Glioblastoma in Its Place: IRF3 Inhibits Invasion.

Siobhan S Pattwell1, Eric C Holland2.   

Abstract

With an unsurpassed capacity for invasion into normal brain tissue, glioblastoma multiforme is the most lethal primary brain tumor. New research suggests that altering a subset of extracellular matrix factors, including interferon regulatory factor (IRF)3 and casein kinase (CK)2, may decrease the migratory potential of these aggressive tumors.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28774478      PMCID： PMC5843370          DOI： 10.1016/j.molmed.2017.07.008

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  10 in total

Review 1.  Extracellular matrix molecules and their receptors: functions in neural development.

Authors:  L F Reichardt; K J Tomaselli
Journal:  Annu Rev Neurosci       Date:  1991       Impact factor: 12.449

2.  Casein kinase II controls TBK1/IRF3 activation in IFN response against viral infection.

Authors:  Min Du; Jinghua Liu; Xia Chen; Yadong Xie; Chuanping Yuan; Yu Xiang; Bing Sun; Ke Lan; Mingzhou Chen; Sharmy J James; Yongliang Zhang; Jin Zhong; Hui Xiao
Journal:  J Immunol       Date:  2015-03-25       Impact factor: 5.422

3.  Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.

Authors:  Tatsuya Ozawa; Markus Riester; Yu-Kang Cheng; Jason T Huse; Massimo Squatrito; Karim Helmy; Nikki Charles; Franziska Michor; Eric C Holland
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

4.  Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.

Authors:  Nora Pencheva; Mark C de Gooijer; Daniel J Vis; Lodewyk F A Wessels; Tom Würdinger; Olaf van Tellingen; René Bernards
Journal:  Cell Rep       Date:  2017-07-05       Impact factor: 9.423

5.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  Glioblastoma: molecular analysis and clinical implications.

Authors:  Jason T Huse; Eric Holland; Lisa M DeAngelis
Journal:  Annu Rev Med       Date:  2012-10-01       Impact factor: 13.739

Review 8.  A neurocentric perspective on glioma invasion.

Authors:  Vishnu Anand Cuddapah; Stefanie Robel; Stacey Watkins; Harald Sontheimer
Journal:  Nat Rev Neurosci       Date:  2014-07       Impact factor: 34.870

9.  Big data visualization identifies the multidimensional molecular landscape of human gliomas.

Authors:  Hamid Bolouri; Lue Ping Zhao; Eric C Holland
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-26       Impact factor: 11.205

10.  Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.

Authors:  Patrick J Cimino; Michael Zager; Lisa McFerrin; Hans-Georg Wirsching; Hamid Bolouri; Bettina Hentschel; Andreas von Deimling; David Jones; Guido Reifenberger; Michael Weller; Eric C Holland
Journal:  Acta Neuropathol Commun       Date:  2017-05-22       Impact factor: 7.801
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.